Fate Therapeutics
FATE
22 hedge funds and large institutions have $52.6M invested in Fate Therapeutics in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 3 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
16% less capital invested
Capital invested by funds: $62.4M → $52.6M (-$9.83M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$1.33M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$135K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$133K |
| 5 |
Goldman Sachs
New York
|
+$91.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$445K |
| 2 |
BCM
Bourgeon Capital Management
Darien,
Connecticut
|
-$97K |
| 3 |
DCMM
DG Capital Management (Massachusetts)
Boston,
Massachusetts
|
-$82K |
| 4 |
Jane Street
New York
|
-$77K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$9.35K |
FATE Hedge Fund Activity: Q3 2014 in Review
22 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2014, worth a combined $52.6M — down 16% from $62.4M a quarter earlier.
Fund positioning in FATE was balanced in Q3 2014: 3 funds opened new positions, 3 closed out, 11 added to existing stakes and 4 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $1.33M. The largest seller was Farallon Capital Management, cutting an estimated $445K.
- 22 institutional investors held Fate Therapeutics (FATE) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $52.6M of Fate Therapeutics stock for Q3 2014, down 16% quarter-over-quarter.
- 3 funds opened new Fate Therapeutics positions in Q3 2014 and 3 closed out, a net change of 0 holders.
- The largest Fate Therapeutics buyer in Q3 2014 was Kingdon Capital Management, an estimated $1.33M added.
- The largest Fate Therapeutics seller in Q3 2014 was Farallon Capital Management, an estimated $445K sold.
Based on aggregated 13F filings for Q3 2014.